Actualités de la communauté

18.05.2020 Mymetics and Baylor College of Medicine start Research Collaboration for Virosome-based Covid-19 Vaccines

Mymetics has started a Covid-19 vaccine development project based on Mymetics’ virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine

Baylor College of Medicine in Texas has developed SARS-CoV and SARS-CoV-2 recombinant proteins and has extensive expertise developing protein-based vaccines from discovery through clinical testing

Baylor and Mymetics will collaborate to evaluate the Baylor SARS recombinant protein antigens linked to Mymetics’ virosomes in preclinical studies with the aim to identify and select the most efficacious and safe formulations to take forward a virosome-based COVID-19 vaccine through product and clinical development

Epalinges, Switzerland, May 18, 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that its subsidiary, Mymetics BV, has signed a Research Collaboration Agreement with Baylor College of Medicine and Texas Children’s Center for Vaccine Development for evaluating their rationally designed recombinant protein-based SARS-CoV and SARS-CoV-2 antigens and combining them with Mymetics’ virosomes for the development of a safe and effective Covid-19 vaccine.

Since the end of April, Mymetics has started a project for the rapid development of a Covid-19 virosome-based vaccine and is thereby partnering with leading academic institutions to explore and select the best SARS-CoV antigens, which could not only be efficacious in protecting against Covid-19 but also safe, affordable and accessible for use in the global population.
Baylor College of Medicine.

Read the full Press Release